GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » 1-Year ROIIC %

Gyre Therapeutics (Gyre Therapeutics) 1-Year ROIIC % : 112.04% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Gyre Therapeutics's 1-Year ROIIC % for the quarter that ended in Dec. 2023 was 112.04%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Gyre Therapeutics's 1-Year ROIIC % or its related term are showing as below:

GYRE's 1-Year ROIIC % is ranked better than
76.32% of 1453 companies
in the Biotechnology industry
Industry Median: -4.79 vs GYRE: 112.04

Gyre Therapeutics 1-Year ROIIC % Historical Data

The historical data trend for Gyre Therapeutics's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics 1-Year ROIIC % Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
1-Year ROIIC %
- -26,538.42 112.04

Gyre Therapeutics Semi-Annual Data
Dec21 Dec22 Dec23
1-Year ROIIC % - -26,538.42 112.04

Competitive Comparison of Gyre Therapeutics's 1-Year ROIIC %

For the Biotechnology subindustry, Gyre Therapeutics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gyre Therapeutics's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's 1-Year ROIIC % falls into.



Gyre Therapeutics 1-Year ROIIC % Calculation

Gyre Therapeutics's 1-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( 21.3379578 (Dec. 2023) - 4.2186552 (Dec. 2022) )/( 63.92 (Dec. 2023) - 48.641 (Dec. 2022) )
=17.1193026/15.279
=112.04%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Gyre Therapeutics  (NAS:GYRE) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Gyre Therapeutics 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gyre Therapeutics (Gyre Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines